News
Sports
Life
Opinion
Business
Advertise
Obituaries
eNewspaper
Legals
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Purple Biotech Ltd.
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
July 25, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
July 02, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
July 10, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
July 01, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
June 27, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
June 01, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
April 25, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
March 28, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
March 14, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
February 27, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
February 13, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
February 01, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
December 20, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
December 14, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Fortifies NT219 Patent Protection
November 02, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
October 19, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Announces $5 Million Registered Direct Offering
October 17, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
October 06, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
October 03, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
September 21, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Reports Second Quarter 2023 Financial Results
August 22, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
July 11, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Debuts Scientific Advisory Board
April 25, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
April 19, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
April 18, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
March 24, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
March 16, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
February 14, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer
February 02, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments
January 03, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Tickers
PPBT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.